Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HC-7366 and Belzutifan in Advanced Renal Cell Carcinoma
NCT06234605Phase 1Recruiting
- Sponsor
- HiberCell
- Start
- Apr 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HC-7366 in renal cell carcinoma (RCC) (2 arms), sponsored by HiberCell. Primary endpoints: Maximum Tolerated Dose at 30 months and Recommended Phase 2 Dose at 30 months. Started Apr 2024; status: recruiting.
02
Drugs
HC-7366
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06234605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06234605.